{
    "nctId": "NCT05831878",
    "briefTitle": "RC48-ADC in HER2-low Advanced Breast Cancer",
    "officialTitle": "Disitamab Vedotin (RC48-ADC) in Patients With HER2-low Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients aged 18-70 years (including 18 years and 70 years)\n* Expected survival \u226512 weeks\n* ECOG 0-1\n* Histologically confirmed invasive advanced or metastatic breast cancer that is incurable and unresectable\n* At least one measurable lesion according to the RECIST 1.1\n* No history of antibody-drug conjugate use\n* Up to one previous chemotherapy for advanced disease\n* Available hormone receptor status. Hormone receptor-positive subjects are allowed to receive no more than two previous endocrine therapy for advanced disease\n* HER2-low tumors, defined as IHC1+ or IHC2+ with negative FISH test\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of thromboembolic events\n* Uncontrolled systemic diseases, including diabetes, hypertension, interstitial lung disease, cirrhosis, etc.\n* Active infections requiring systemic treatment\n* Pregnant or lactating\n* Presence of brain metastases and/or carcinomatous meningitis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}